# US 2021/0071252 A1 · Non-coding rnas (ncrna) for the diagnosis of cognitive disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0071252 A1
- Document ID: US20210071252A1
- Status: Published application
- Kind: A1
- Application number: 16/644,812
- Filed: 2018-09-05
- Published: 2021-03-11
- Earliest claimed: 2017-09-05
- Assignees: Amoneta Diagnostics
- Applicants: Amoneta Diagnostics
- Inventors: Hueseyin FIRAT; Saliha MOUSSAOUI; Eric SCHORDAN
- Web page: https://patentgrep.com/patent/US20210071252A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention describes a method for the diagnosis of a cognitive disorder including but not limited to Alzheimer disease in a subject at risk of having or developing a cognitive disorder.

## Claims

### Claim 1

A method for diagnosing or treating a cognitive disorder including but not limited to Alzheimer disease in a subject at risk of having or developing a cognitive disorder, comprising:
(a) isolating a biological sample from the subject;
(b) detecting a level of expression in a ncRNA (miRNA and/or lncRNA) signature, the ncRNA signature comprising or consisting of at least one ncRNA (miRNA and/or lncRNA) selected from 406 miRNAs listed in Table 1 and 1008 lncRNAs listed in Table 5 in the biological sample from said subject;
(c) comparing the level of expression in the sample to a level of expression in a reference, wherein an increased or decreased level of expression in the sample compared to the level in the reference identifies the subject having a cognitive disorder or being at risk of developing a cognitive disorder.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the ncRNA signature comprises ncRNAs selected from the group consisting of:
(i) miR.99a.5p;
(ii) 7 miRNAs of miR.99a.5p, miR.378d, miR.100.5p, miR.193b.3p, miR.34a.5p, miR.1306.5p, and miR.1229.3p;
(iii) 3 miRNAs of miR1220.3p, miR378d and miR99a.5p;
(iv) 11 mRNAs of miR.99a.5p, miR.1229.3p, miR.100.5p, miR.378d, miR.193b.3p, miR.1306.5p, miR.195.5p, miR.532.3p, miR.125b.5p, miR.34a.5p, and miR.6880.5p;
(v) 15 miRNAs of miR.23a.5p, miR.6880.5p, miR.7111.5p, miR.6812.5p, miR.6738.5p, miR.5196.5p, miR.6894.5p, miR.8085, miR.4463, miR.2392, miR.144.3p, miR.192.5p, miR.193b.3p, miR.194.5p, and miR.122.5p;
(vi) 13 lncRNAs of lnc-DLG5-1:1, lnc-EBLN1-1:4, lnc-FAT1-7:2, lnc-PRR5-5:1, lnc-RBKS-6:1, lnc-FOXD4L5-35:1, lnc-TENM3-3:3, lnc-FAM133B-2: 1, lnc-ZNF726-1:3, lnc-AP3M1-1:1, lnc-DUSP10-6:1, lnc-TPPP-1:2, and LINC01206:20;
(vii) 7 lncRNAs of LINC02345:11, lnc-EBLN1-1:4, lnc-TPPP-1:2, lnc-TENM3-3:3, lnc-FAT1-7:2, lnc-DKK1-5:3, and lnc-TACSTD2-2:4;
(viii) 12 lnc RNAs of lnc-TPPP-1:2, ARRDC3-AS1:7, lnc-TENM3-3:5, lnc-TENM3-3:4, lnc-QRFP-5:1, lnc-CRYBB1-1:1, lnc-MGST3-1:3, lnc-FAM49B-8:1, HAND2-AS 1:70, lnc-TMEM185B-12:7, lnc-CNDP1-7:1, and lnc-C21orf58-1:2;
(ix) 3 lncRNAs of lnc-TENM3-3:3, lnc-MARCH4-2:7, and lnc-LRRC1-5:2;
(x) 7 lncRNAs of lnc-TPPP-1:2, lnc-TENM3-3:3, lnc-TMEM185B-12:7, lnc-NAXD-6:5, lnc-HECA-6:1, lnc-COMMD6-10:1, and MIR29B2CHG:46;
(xi) 18 lncRNAs of lnc-TPPP-1:2, LINC02345:11, lnc-ZNF273-4:4, lnc-TACC2-8:6, LINC01206:20, lnc-05orf67-3:1, HAND2-AS1:58, lnc-PRDM9-20:1, lnc-CLK1-1:7, lnc-DNALI1-5:4, RORB-AS 1:6, lnc-TPPP-1:3, lnc-BMS 1-2:1, lnc-ADRB 1-4:1, lnc-XXYLT1-5:1, MIR99AHG:104, LINC01748:17, and lnc-AKR1E2-15:1;
(xii) 28 miRNAs listed in Table 2;
(xiii) 74 miRNAs listed in Table 3;
(xiv) 33 lncRNAs listed in Table 6;
(xv) 60 lncRNAs listed in Table 7;
(xvi) 32 lncRNAs listed in Table 8;
(xvii) 84 lncRNAs listed in Table 9; and
(xviii) 94 lncRNAS listed in Table 10.

### Claim 3 (depends on 1)

A method according to claim 1, wherein in step (b) the expression level of ncRNAs is detected in combination with another biomarker suitable for detection of a cognitive disorder such as neurocognitive tests, neuroimaging methods and/or CSF biomarkers.

### Claim 4 (depends on 1)

A method according to claim 1 for monitoring the development or progression of a cognitive disorder in a subject suffering from a loss or impairment of cognitive function or dementia, said method comprising steps (a), (b) and (c), and (d) designing the therapeutic treatment according to the said identified cognitive disorder.

### Claim 5 (depends on 1)

A method for treating a subject suffering from a progressive impairment or loss of cognitive function or dementia, said method comprising:
(a) diagnosing the cognitive disorder associated to the progressive impairment or loss of cognitive function or dementia in said patient using the method according to claim 1, and
(b) adapting the therapeutic treatment to the results obtained in step (a).

### Claim 6 (depends on 1)

A method for adapting therapeutic strategy to a subject suffering from a progressive impairment or loss of cognitive functions or dementia, the said method comprising the following steps:
(a) diagnosing or monitoring the progressive impairment or loss of cognitive function or dementia in said patient using the method according to claim 1 and
(b) modifying consequently the therapeutic strategy of the patient.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the biological sample is selected from blood, plasma, serum, saliva, tear, urine or cerebrospinal fluid.

### Claim 8 (depends on 1)

A method according to claim 1, wherein a cognitive disorder or any dementia type is diagnosed (differentiation versus healthy controls) or wherein the specific type of dementia is diagnosed versus other types of dementia including and not limited to Alzheimer (AD), mild cognitive impairment (MCI) of AD type, Frontotemporal dementia (FTD) and MCI of FTD type, Dementia with Lewy body (DLB) and MCI of DLB type, Parkinson's disease dementia (PDD) and MCI of PDD type, Vascular dementia, Progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).

### Claim 9

A kit for diagnosing and/or monitoring a cognitive disorder including but not limited to AD, comprising at least one reagent for the determination of a ncRNA expression profile comprising or consisting of at least one ncRNA (miRNA and/or lncRNA) selected from 406 miRNAs listed in Table 1 and 1008 lncRNAs listed in Table 5.

### Claim 10 (depends on 9)

The kit according to claim 9, wherein the ncRNA expression profile comprises ncRNAs selected from the group consisting of:
(i) miR.99a.5p;
(ii) 7 miRNAs of miR.99a.5p, miR.378d, miR.100.5p, miR.193b.3p, miR.34a.5p, miR.1306.5p, and miR.1229.3p;
(iii) 3 miRNAs of miR1220.3p, miR378d and miR99a.5p;
(iv) 11 mRNAs of miR.99a.5p, miR.1229.3p, miR.100.5p, miR.378d, miR.193b.3p, miR.1306.5p, miR.195.5p, miR.532.3p, miR.125b.5p, miR.34a.5p, and miR.6880.5p;
(v) 15 miRNAs of miR.23a.5p, miR.6880.5p, miR.7111.5p, miR.6812.5p, miR.6738.5p, miR.5196.5p, miR.6894.5p, miR.8085, miR.4463, miR.2392, miR.144.3p, miR.192.5p, miR.193b.3p, miR.194.5p, and miR.122.5p;
(vi) 13 lncRNAs of lnc-DLG5-1:1, lnc-EBLN1-1:4, lnc-FAT1-7:2, lnc-PRR5-5:1, lnc-RBKS-6:1, lnc-FOXD4L5-35:1, lnc-TENM3-3:3, lnc-FAM133B-2:1, lnc-ZNF726-1:3, lnc-AP3M1-1:1, lnc-DUSP10-6:1, lnc-TPPP-1:2, and LINC01206:20;
(vii) 7 lncRNAs of LINC02345:11, lnc-EBLN1-1:4, lnc-TPPP-1:2, lnc-TENM3-3:3, lnc-FAT1-7:2, lnc-DKK1-5:3, and lnc-TACSTD2-2:4;
(viii) 12 lnc RNAs of lnc-TPPP-1:2, ARRDC3-AS1:7, lnc-TENM3-3:5, lnc-TENM3-3:4, lnc-QRFP-5:1, lnc-CRYBB 1-1:1, lnc-MGST3-1:3, lnc-FAM49B-8:1, HAND2-AS 1:70, lnc-TMEM185B-12:7, lnc-CNDP1-7:1, and lnc-C21orf58-1:2;
(ix) 3 lncRNAs of lnc-TENM3-3:3, lnc-MARCH4-2:7, and lnc-LRRC1-5:2;
(x) 7 lncRNAs of lnc-TPPP-1:2, lnc-TENM3-3:3, lnc-TMEM185B-12:7, lnc-NAXD-6:5, lnc-HECA-6:1, lnc-COMMD6-10:1, and MIR29B2CHG:46;
(xi) 18 lncRNAs of lnc-TPPP-1:2, LINC02345:11, lnc-ZNF273-4:4, lnc-TACC2-8:6, LINC01206:20, lnc-05orf67-3:1, HAND2-AS1:58, lnc-PRDM9-20:1, lnc-CLK1-1:7, lnc-DNALI1-5:4, RORB-AS 1:6, lnc-TPPP-1 :3, lnc-BMS 1-2:1, lnc-ADRB 1-4:1, lnc-XXYLT1-5: 1, MIR99AHG: 104, LINC01748: 17, and lnc-AKR1E2-15:1;
(xii) 28 miRNAs listed in Table 2;
(xiii) 74 miRNAs listed in Table 3;
(xiv) 33 lncRNAs listed in Table 6;
(xv) 60 lncRNAs listed in Table 7;
(xvi) 32 lncRNAs listed in Table 8;
(xvii) 84 lncRNAs listed in Table 9; and
(xviii) 94 lncRNAS listed in Table 10.

### Claim 11 (depends on 9)

The kit according to claim 9, wherein the at least one reagent comprises specific oligonucleotides complementary to the ncRNAs of interest.

### Claim 12

A targeted sequencing panel for next generation sequencing, comprising nucleic acids specific for at least one ncRNA (miRNA and/or lncRNA) selected from 406 miRNAs listed in Table 1 and 1008 lncRNAs listed in Table 5.

### Claim 13 (depends on 12)

The sequencing panel according to claim 12, wherein the at least one ncRNA comprises ncRNAs selected from the group consisting of:
(i) miR.99a.5p;
(ii) 7 miRNAs of miR.99a.5p, miR.378d, miR.100.5p, miR.193b.3p, miR.34a.5p, miR.1306.5p, and miR.1229.3p;
(iii) 3 miRNAs of miR1220.3p, miR378d and miR99a.5p;
(iv) 11 mRNAs of miR.99a.5p, miR.1229.3p, miR.100.5p, miR.378d, miR.193b.3p, miR.1306.5p, miR.195.5p, miR.532.3p, miR.125b.5p, miR.34a.5p, and miR.6880.5p;
(v) 15 miRNAs of miR.23a.5p, miR.6880.5p, miR.7111.5p, miR.6812.5p, miR.6738.5p, miR.5196.5p, miR.6894.5p, miR.8085, miR.4463, miR.2392, miR.144.3p, miR.192.5p, miR.193b.3p, miR.194.5p, and miR.122.5p;
(vi) 13 lncRNAs of lnc-DLG5-1:1, lnc-EBLN1-1:4, lnc-FAT1-7:2, lnc-PRR5-5:1, lnc-RBKS-6:1, lnc-FOXD4L5-35:1, lnc-TENM3-3:3, lnc-FAM133B-2: 1, lnc-ZNF726-1:3, lnc-AP3M1-1:1, lnc-DUSP10-6:1, lnc-TPPP-1:2, and LINC01206:20;
(vii) 7 lncRNAs of LINC02345:11, lnc-EBLN1-1:4, lnc-TPPP-1:2, lnc-TENM3-3:3, lnc-FAT1-7:2, lnc-DKK1-5:3, and lnc-TACSTD2-2:4;
(viii) 12 lnc RNAs of lnc-TPPP-1:2, ARRDC3-AS1:7, lnc-TENM3-3:5, lnc-TENM3-3:4, lnc-QRFP-5:1, lnc-CRYBB 1-1:1, lnc-MGST3-1:3, lnc-FAM49B-8:1, HAND2-AS 1:70, lnc-TMEM185B-12:7, lnc-CNDP1-7:1, and lnc-C21orf58-1:2;
(ix) 3 lncRNAs of lnc-TENM3-3:3, lnc-MARCH4-2:7, and lnc-LRRC1-5:2;
(x) 7 lncRNAs of lnc-TPPP-1:2, lnc-TENM3-3:3, lnc-TMEM185B-12:7, lnc-NAXD-6:5, lnc-HECA-6:1, lnc-COMMD6-10:1, and MIR29B2CHG:46;
(xi) 18 lncRNAs of lnc-TPPP-1:2, LINC02345:11, lnc-ZNF273-4:4, lnc-TACC2-8:6, LINC01206:20, lnc-05orf67-3:1, HAND2-AS1:58, lnc-PRDM9-20:1, lnc-CLK1-1:7, lnc-DNALI1-5:4, RORB-AS1:6, lnc-TPPP-1:3, lnc-BMS1-2:1, lnc-ADRB1-4:1, lnc-XXYLT1-5:1, MIR99AHG:104, LINC01748:17, and lnc-AKR1E2-15:1;
(xii) 28 miRNAs listed in Table 2;
(xiii) 74 miRNAs listed in Table 3;
(xiv) 33 lncRNAs listed in Table 6;
(xv) 60 lncRNAs listed in Table 7;
(xvi) 32 lncRNAs listed in Table 8;
(xvii) 84 lncRNAs listed in Table 9; and
(xviii) 94 lncRNAS listed in Table 10.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the method further comprises a step of administering at least one therapeutic agent to the subject in order to treat the cognitive disorder.
